Localized immune tolerance from FasL-functionalized PLG scaffolds
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Intraportal allogeneic islet transplantation has been demonstrated as a potential therapy for type 1 diabetes (T1D). The placement of islets into the liver and chronic immunosuppression to control rejection are two major limitations of islet transplantation. We hypothesize that localized immunomodulation with a novel form of FasL chimeric with streptavidin, SA-FasL, can provide protection and long-term function of islets at an extrahepatic site in the absence of chronic immunosuppression. Allogeneic islets modified with biotin and engineered to transiently display SA-FasL on their surface showed sustained survival following transplantation on microporous scaffolds into the peritoneal fat in combination with a short course (15 days) of rapamycin treatment. The challenges with modifying islets for clinical translation motivated the modification of scaffolds with SA-FasL as an off-the-shelf product. Poly(lactide-co-glycolide) (PLG) was conjugated with biotin and fabricated into particles and subsequently formed into microporous scaffolds to allow for rapid and efficient conjugation with SA-FasL. Biotinylated particles and scaffolds efficiently bound SA-FasL and induced apoptosis in cells expressing Fas receptor (FasR). Scaffolds functionalized with SA-FasL were subsequently seeded with allogeneic islets and transplanted into the peritoneal fat under the short-course of rapamycin treatment. Scaffolds modified with SA-FasL had robust engraftment of the transplanted islets that restored normoglycemia for 200 days. Transplantation without rapamycin or without SA-FasL did not support long-term survival and function. This work demonstrates that scaffolds functionalized with SA-FasL support allogeneic islet engraftment and long-term survival and function in an extrahepatic site in the absence of chronic immunosuppression with significant potential for clinical translation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931
International trial of the Edmonton protocol for islet transplantation
Shapiro, A. M. J., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061267 · Cited by 1,942 · cited 5×
“However, broad application of clinical allogeneic islet transplantation is limited by the chronic use of immunosuppression to control immune rejection and its sequelae [5], and transplantation into the liver, which compromises immediate post-graft islet engraftment as well as longterm survival [7].”
BackgroundInfluentialHering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1988 · Cited by 645
Bellin, M. D., Barton, F. B., Heitman, A., Harmon, J. V., Kandaswamy, R., Balamurugan, A. N., Sutherland, D. E. R., Alejandro, R., & Hering, B. J. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03977.x · Cited by 350
Thompson, D. M., Meloche, M., Ao, Z., Paty, B., Keown, P., Shapiro, R. J., Ho, S., Worsley, D., Fung, M., Meneilly, G., et al. (2011) · Transplantation · doi:10.1097/tp.0b013e31820437f3 · Cited by 213 · cited 4×
“Intraportal allogeneic islet transplantation has been demonstrated as a potential therapy for type 1 diabetes (T1D).”
BackgroundInfluentialHeaden, D. M., Woodward, K. B., Coronel, M. M., Shrestha, P., Weaver, J. D., Zhao, H., Tan, M., Hunckler, M. D., Bowen, W. S., Johnson, C. T., et al. (2018) · Nature Materials · doi:10.1038/s41563-018-0099-0 · Cited by 175 · cited 2×
“play a dominant role for the induced tolerance in our model as published previously [75, 76], we speculate that induction of apoptosis in Teff cells and generation and maintenance of Treg cells are the two potential regulatory steps targeted by SA-FasL and rapamycin for the observed synergy.”
BackgroundSelf-citationYolcu, E. S., Zhao, H., Bandura-Morgan, L., Lacelle, C., Woodward, K. B., Askenasy, N., & Shirwan, H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003266 · Cited by 82
Self-citationWoodward, K. B., Zhao, H., Shrestha, P., Batra, L., Tan, M., Grimany-Nuno, O., Bandura-Morgan, L., Askenasy, N., Shirwan, H., & Yolcu, E. S. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15747 · Cited by 35
Self-citation
Cited by
Grattoni, A., Korbutt, G., Tomei, A. A., García, A. J., Pepper, A. R., Stabler, C., Brehm, M., Papas, K., Citro, A., Shirwan, H., et al. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01029-0 · Cited by 92
Self-citationWang, X., Wang, K., Yu, M., Velluto, D., Hong, X., Wang, B., Chiu, A., Melero-Martin, J. M., Tomei, A. A., & Ma, M. (2022) · Science Advances · doi:10.1126/sciadv.abn0071 · Cited by 62
Samojlik, M. M., & Stabler, C. L. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.039 · Cited by 38
Woodward, K. B., Zhao, H., Shrestha, P., Batra, L., Tan, M., Grimany-Nuno, O., Bandura-Morgan, L., Askenasy, N., Shirwan, H., & Yolcu, E. S. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15747 · Cited by 35
Self-citationAdvances in Islet Transplantation and the Future of Stem Cell–Derived Islets to Treat Diabetes
Kieffer, T. J., Hoesli, C. A., & Shapiro, A. M. J. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041624 · Cited by 7
Metadata
- Authors
- Skoumal, M., Woodward, K. B., Zhao, H., Wang, F., Yolcu, E. S., Pearson, R. M., Hughes, K. R., García, A. J., Shea, L. D., & Shirwan, H.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 192
- Pages
- 271-281
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2901774981
- Cited by
- 49
- References
- 8
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Localized immune tolerance from FasL-functionalized PLG scaffolds. https://app.cochat.ai/papers/10.1016/j.biomaterials.2018.11.015
- The paper
- Skoumal, M., Woodward, K. B., Zhao, H., Wang, F., Yolcu, E. S., Pearson, R. M., Hughes, K. R., García, A. J., Shea, L. D., & Shirwan, H. (2019). Localized immune tolerance from FasL-functionalized PLG scaffolds. Biomaterials. https://doi.org/10.1016/j.biomaterials.2018.11.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.